EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients Japan East Cancer Center Breast Cancer Consortium



Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients Japan East Cancer Center Breast Cancer Consortium



EJC Supplements 2(3): 131, March




(PDF 0-2 workdays service: $29.90)

Accession: 035349872

Download citation: RISBibTeXText



Related references

Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 33(10): 1411-1415, 2006

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Journal of Clinical Oncology 26(15_suppl): 1003-1003, 2016

Study of three-weekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 32(3): 335-339, 2005

Weekly docetaxel and trastuzumab for her-2-overexpressing metastatic breast cancer efficacy and correlation with biological markers in a phase II, multicenter study. EJC Supplements 2(3): 137-138, March, 2004

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Journal of Clinical Oncology 26(15_suppl): 1057-1057, 2016

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 20(7): 1800-1808, 2002

A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 66(1): 38-45, 2004

Phase II trial of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Breast Cancer Research & Treatment 64(1): 80, November, 2000

Biweekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 33(8): 1081-1085, 2006

A phase II trial of weekly docetaxel and trastuzumab in metastatic breast cancer. European Journal of Cancer Supplements 6(7): 179-180, 2008

Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clinical Breast Cancer 9(1): 23-28, 2009

Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC). Journal of Clinical Oncology 26(15_suppl): 1032-1032, 2016

Phase II trial to study the efficacy and toxicity of combined docetaxel (D), carboplatin (C), +/- trastuzumab (T) administered weekly (W) in patients (pts) with HER2/neu +/- metastatic breast cancer (MBC). Journal of Clinical Oncology 23(16_suppl): 832-832, 2016

Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial. Cancer ChemoTherapy and Pharmacology 68(4): 1009-1016, 2011

Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clinical Breast Cancer 4(6): 420-427, 2004